Lake Street Capital Lowers LifeMD (NASDAQ:LFMD) Price Target to $8.00

LifeMD (NASDAQ:LFMD) had its target price cut by Lake Street Capital from $14.00 to $8.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Lake Street Capital’s target price suggests a potential upside of 103.10% from the stock’s previous close.

LFMD has been the topic of several other reports. B. Riley decreased their price objective on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday. Zacks Research raised LifeMD from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. BTIG Research dropped their price target on LifeMD from $18.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeMD in a research report on Wednesday, October 8th. Finally, KeyCorp decreased their target price on LifeMD from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Wednesday, August 6th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.71.

LifeMD Price Performance

LifeMD stock traded down $0.79 during mid-day trading on Tuesday, hitting $3.94. 5,339,366 shares of the company were exchanged, compared to its average volume of 1,524,952. The company has a market capitalization of $186.79 million, a PE ratio of -18.79 and a beta of 1.57. The business has a fifty day moving average of $6.05 and a 200 day moving average of $8.71. LifeMD has a 1-year low of $3.43 and a 1-year high of $15.84. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Monday, November 17th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $47.28 million for the quarter, compared to the consensus estimate of $62.07 million. During the same quarter in the previous year, the company earned $0.09 EPS. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts expect that LifeMD will post -0.56 earnings per share for the current year.

Insider Transactions at LifeMD

In other news, insider Nicholas P. Alvarez sold 75,000 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total value of $444,000.00. Following the transaction, the insider owned 605,000 shares of the company’s stock, valued at approximately $3,581,600. This trade represents a 11.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 18.40% of the company’s stock.

Hedge Funds Weigh In On LifeMD

Hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC boosted its position in shares of LifeMD by 17.5% in the 1st quarter. CWM LLC now owns 9,050 shares of the company’s stock worth $49,000 after purchasing an additional 1,351 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of LifeMD by 148.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock worth $50,000 after acquiring an additional 2,185 shares in the last quarter. Quarry LP acquired a new stake in shares of LifeMD during the third quarter worth about $52,000. Tower Research Capital LLC TRC lifted its holdings in shares of LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares in the last quarter. Finally, King Wealth Management Group acquired a new position in shares of LifeMD in the 3rd quarter valued at approximately $68,000. 35.52% of the stock is owned by institutional investors.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.